MCID: BLD131
MIFTS: 62

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Bladder Urothelial Carcinoma

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 15
Transitional Cell Carcinoma of the Bladder 29 6
Transitional Cell Carcinoma of Bladder 12 72
Bladder Transitional Cell Carcinoma 12 17
Urinary Bladder Urothelial Carcinoma 12
Carcinoma Transitional Cell Bladder 55
Urothelial Bladder Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4006
NCIt 50 C39851
UMLS 72 C0279680

Summaries for Bladder Urothelial Carcinoma

Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to bladder disease and transitional cell carcinoma. An important gene associated with Bladder Urothelial Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Valrubicin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include prostate, lymph node and testes, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Bladder Urothelial Carcinoma

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 bladder disease 31.4 TP53 FGFR3 ERBB2
2 transitional cell carcinoma 31.4 TP53 HRAS FGFR3 ERBB2 BRAF
3 non-invasive bladder papillary urothelial neoplasm 31.1 TP53 FGFR3
4 lynch syndrome 31.0 TP53 KRAS CTNNB1 BRAF
5 undifferentiated pleomorphic sarcoma 30.9 PIK3CA KRAS IDH1
6 adenoma 30.8 TP53 KRAS CTNNB1 BRAF
7 exanthem 30.7 KRAS HRAS ERBB2
8 intrahepatic cholangiocarcinoma 30.7 TUG1 TP53 KRAS IDH1 CTNNB1
9 nevus, epidermal 30.6 PIK3CA NRAS KRAS HRAS FGFR3
10 colorectal adenocarcinoma 30.6 TP53 KRAS HRAS CTNNB1 BRAF
11 carcinosarcoma 30.5 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
12 suppression of tumorigenicity 12 30.5 TP53 PIK3CA IDH1 HRAS CTNNB1 BRAF
13 renal cell carcinoma, papillary, 1 29.9 TP53 PIK3CA NRAS NFE2L2 HRAS FGFR3
14 retinoblastoma 29.9 TP53 MEG3 MALAT1 HOTAIR
15 renal cell carcinoma, nonpapillary 29.6 TUG1 PVT1 MALAT1 HOTAIR GAS5 CRNDE
16 cholangiocarcinoma 29.6 TUG1 TP53 PIK3CA MALAT1 KRAS IDH1
17 bladder cancer 29.5 TUG1 TP53 PVT1 MEG3 MALAT1 KRAS
18 squamous cell carcinoma 29.4 TUG1 TP53 PIK3CA MALAT1 HRAS HOTAIR
19 gastric adenocarcinoma 29.1 TP53 PIK3CA NRAS KRAS HRAS HOTAIR
20 adenocarcinoma 29.0 TP53 PIK3CA MAP2K1 MALAT1 KRAS HRAS
21 thyroid cancer, nonmedullary, 1 28.4 PVT1 MEG3 MALAT1 HOTAIR GAS5 CRNDE
22 glioma 27.4 TP53 PVT1 PIK3CA MEG3 MALAT1 IDH1
23 cervical cancer 27.2 TUG1 TP53 PVT1 PIK3CA NFE2L2 MEG3
24 prostate cancer 27.1 TUG1 TP53 PVT1 PIK3CA MEG3 MAP2K1
25 pancreatic cancer 27.0 TUG1 TP53 PVT1 PIK3CA MEG3 MAP2K1
26 breast cancer 26.8 TUG1 TP53 PVT1 PIK3CA MEG3 MALAT1
27 hepatocellular carcinoma 25.8 TUG1 TP53 PVT1 PIK3CA NRAS NFE2L2
28 colorectal cancer 25.8 TUG1 TP53 PVT1 PIK3CA NRAS NFE2L2
29 non-papillary transitional cell carcinoma of the bladder 12.7
30 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.6
31 non-invasive bladder urothelial carcinoma 12.5
32 clear cell variant infiltrating bladder urothelial carcinoma 12.5
33 micropapillary variant infiltrating bladder urothelial carcinoma 12.5
34 lipid-cell variant infiltrating bladder urothelial carcinoma 12.5
35 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.5
36 nested variant infiltrating bladder urothelial carcinoma 12.5
37 microcystic variant infiltrating bladder urothelial carcinoma 12.5
38 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.4
39 invasive bladder transitional cell carcinoma 11.9
40 small cell carcinoma of the bladder 11.6
41 dermatosis papulosa nigra 11.0 PIK3CA FGFR3
42 adult hepatocellular carcinoma 11.0 TP53 PIK3CA CTNNB1
43 uterine corpus serous adenocarcinoma 11.0 TP53 PIK3CA ERBB2
44 breast squamous cell carcinoma 10.9 TP53 PIK3CA ERBB2
45 uterine body mixed cancer 10.9 TP53 PIK3CA ERBB2
46 uterine corpus cancer 10.9 TP53 PIK3CA ERBB2
47 rare adenocarcinoma of the breast 10.9 TP53 PIK3CA KRAS
48 nevus of ota 10.9 TP53 BRAF
49 malignant spiradenoma 10.9 TP53 PIK3CA
50 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.9 TP53 PIK3CA KRAS

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.63 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.63 KRAS
3 Decreased viability GR00107-A-1 10.63 MAP2K1
4 Decreased viability GR00221-A-1 10.63 FGFR1 FGFR3 HRAS KRAS PIK3CA NRAS
5 Decreased viability GR00221-A-2 10.63 FGFR1 FGFR3 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-3 10.63 FGFR3 HRAS ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 10.63 PIK3CA BRAF ERBB2
8 Decreased viability GR00301-A 10.63 KRAS BRAF
9 Decreased viability GR00342-S-1 10.63 MAP2K1
10 Decreased viability GR00342-S-2 10.63 MAP2K1
11 Decreased viability GR00342-S-3 10.63 MAP2K1
12 Decreased viability GR00381-A-1 10.63 KRAS BRAF
13 Decreased viability GR00402-S-2 10.63 FGFR1 FGFR3 HRAS KRAS PIK3CA BRAF
14 Decreased cell migration GR00055-A-1 9.73 BRAF CTNNB1 FGFR3 HRAS KRAS PIK3CA
15 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 CTNNB1 ERBB2 FGFR3 HRAS NRAS
16 Increased cell migration GR00055-A-3 9.02 BRAF CTNNB1 HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.37 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
2 behavior/neurological MP:0005386 10.35 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
3 cardiovascular system MP:0005385 10.35 BRAF CTNNB1 ERBB2 FGFR1 HRAS KRAS
4 homeostasis/metabolism MP:0005376 10.35 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
5 cellular MP:0005384 10.34 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
6 craniofacial MP:0005382 10.33 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
7 digestive/alimentary MP:0005381 10.32 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
8 mortality/aging MP:0010768 10.31 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
9 integument MP:0010771 10.3 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
10 embryo MP:0005380 10.27 BRAF CTNNB1 ERBB2 FGFR1 KRAS MAP2K1
11 endocrine/exocrine gland MP:0005379 10.27 BRAF CTNNB1 ERBB2 FGFR1 HRAS KRAS
12 neoplasm MP:0002006 10.22 BRAF CTNNB1 ERBB2 FGFR3 HRAS KRAS
13 nervous system MP:0003631 10.2 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
14 normal MP:0002873 10.14 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
15 limbs/digits/tail MP:0005371 10.11 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
16 hearing/vestibular/ear MP:0005377 10.09 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
17 no phenotypic analysis MP:0003012 10.03 CTNNB1 FGFR1 FGFR3 HRAS KRAS NRAS
18 renal/urinary system MP:0005367 9.92 BRAF CTNNB1 FGFR1 FGFR3 HRAS KRAS
19 reproductive system MP:0005389 9.91 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
20 respiratory system MP:0005388 9.81 BRAF CTNNB1 ERBB2 FGFR3 HRAS IDH1
21 pigmentation MP:0001186 9.77 BRAF CTNNB1 KRAS NRAS TP53
22 skeleton MP:0005390 9.77 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
23 vision/eye MP:0005391 9.28 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1

Drugs & Therapeutics for Bladder Urothelial Carcinoma

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valrubicin Approved Phase 3 56124-62-0 41744
2
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 14956 5280965
4
Aminolevulinic acid Approved Phase 3 106-60-5 137
5
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
6
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
7
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
8
Pembrolizumab Approved Phase 3 1374853-91-4
9
Ramucirumab Approved, Investigational Phase 3 947687-13-0
10
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
11
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
Vinblastine Approved Phase 3 865-21-4 241903 13342
14
leucovorin Approved Phase 3 58-05-9 143 6006
15
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
16
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
17
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
18
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
19
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
20
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
21 Tocotrienol Investigational Phase 3 6829-55-6
22
Levulinic acid Experimental Phase 3 123-76-2 11579
23
Fenretinide Investigational Phase 3 65646-68-6
24
BCG vaccine Investigational Phase 3
25 Tocopherols Phase 3
26 Tocotrienols Phase 3
27 Liposomal amphotericin B Phase 2, Phase 3
28 Antiparasitic Agents Phase 3
29 Antiprotozoal Agents Phase 3
30 Photosensitizing Agents Phase 3
31 Antioxidants Phase 3
32 Vitamins Phase 3
33 Vitamin B3 Phase 3
34 Nicotinic Acids Phase 3
35 Hypolipidemic Agents Phase 3
36 Lipid Regulating Agents Phase 3
37 Vasodilator Agents Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Vaccines Phase 3
40 Pharmaceutical Solutions Phase 3
41 Dermatologic Agents Phase 3
42 Anti-Bacterial Agents Phase 3
43 Fluoroquinolones Phase 3
44 Antibiotics, Antitubercular Phase 3
45 Topoisomerase Inhibitors Phase 3
46 Cytochrome P-450 Enzyme Inhibitors Phase 3
47 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
48 Folic Acid Antagonists Phase 3
49
Liposomal doxorubicin Phase 3 31703
50 Folate Phase 3

Interventional clinical trials:

(show top 50) (show all 186)
# Name Status NCT ID Phase Drugs
1 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
2 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
3 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
4 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
5 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
6 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
7 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
8 Phase III Randomized Chemoprevention Study of Selenium on the Recurrence of Non-invasive Bladder Cancer Completed NCT00729287 Phase 3
9 Phase III Randomized, Double-Blind Study of DFMO vs. Placebo in Low Grade Superficial Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
10 Megadose Vitamins as Chemoprevention of Transitional Cell Carcinoma of the Bladder Completed NCT00003623 Phase 3
11 Phase III Study Comparing Sequential Chemotherapy (AG-ITP) To Cisplatin And Gemcitabine As Adjuvant Treatment After Cystectomy For Transitional Cell Carcinoma Of The Bladder Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
12 Randomised Trial of Selective Bladder Preservation Against Radical Excision (Cystectomy) in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder - Feasibility Study Completed NCT00867347 Phase 3
13 A Multicenter Randomized Trial of Radical Radiotherapy With Carbogen in the Radical Treatment of Locally Advanced Bladder Cancer Completed NCT00033436 Phase 3 carbogen
14 A Phase III Randomized Trial of Either M-VAC or Paclitaxel + Carboplatin as Postoperative Adjuvant Therapy in Patients With Muscle-Invasive Transitional Cell Carcinoma of the Bladder at High-Risk for Relapse Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
15 A RANDOMIZED TRIAL OF RADICAL RADIOTHERAPY IN pT1G3 NXM0 BLADDER CANCER Completed NCT00002490 Phase 3 mitomycin C
16 Phase IIb/III Chemoprevention Trial of Celecoxib to Prevent Recurrence of Superficial Bladder Cancer Completed NCT00006124 Phase 2, Phase 3 celecoxib;placebo
17 Randomized Chemoprevention Trial With 4-HPR (Fenretinide) in Superficial Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
18 Phase III Trial of Methotrexate, Vinblastine, Doxorubicin and Cisplatin vs Carboplatin and Paclitaxel in Advanced Carcinoma of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
19 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
20 Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy. Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
21 Randomized Phase II/III Study Assessing Gemcitabine/Carboplatin And Methotrexate/Carboplatin/Vinblastine In Previously Untreated Patients With Advanced Urothelial Cancer Ineligible For Cisplatin Based Chemotherapy Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
22 A Phase III Blinded Study of Immediate Post TURBT Instillation of Gemcitabine Versus Saline in Patients With Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
23 Sequential Bacillus Calmette-Guérin and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin Alone for High Risk Superficial Bladder Cancer: a Prospective Randomised Study Completed NCT01442519 Phase 3 electromotive mitomycin
24 S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
25 Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation Recruiting NCT03244384 Phase 3
26 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy Active, not recruiting NCT02426125 Phase 3 Ramucirumab;Docetaxel;Placebo
27 The Effect of Fluoroquinolones on the Disease-Free Interval in Patients With Stage Ta Transitional Cell Carcinoma of the Bladder Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
28 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
29 A Phase III Study of IRESSA in Combination With Intravesical BCG Versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder Terminated NCT00352079 Phase 3 gefitinib
30 Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial Terminated NCT00042887 Phase 3 mitomycin C
31 MVAC (Methotrexate, Vinblastine, Adriamycin, and Cisplatin) in Organ-Confined Bladder Cancer Based on p53 Status Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
32 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
33 A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder Unknown status NCT01616875 Phase 2 Cabazitaxel + Cisplatin chemotherapy
34 First Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma of the Bladder With a Combination of Cisplatin-Paclitaxel-Gemcitabine Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
35 A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
36 A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01215877 Phase 2 Tesetaxel
37 Bladder Cancer: Open Versus Laparoscopic or Robotic Cystectomy. A Study to Determine the Feasibility of Randomization to Open Versus Minimal Access Cystectomy in Patients With Bladder Cancer. Unknown status NCT01196403 Phase 2
38 A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy Unknown status NCT01118039 Phase 2 sunitinib malate
39 Treatment of Patients With Transitional-Cell Carcinoma of the Urothelial Tract With Gemcitabine, Docetaxel and Filgrastim Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
40 Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment. Unknown status NCT01620970 Phase 2 PF03446962
41 A Phase Ib/II Trial of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
42 A Phase II Study of R115777 (Zarnestra) in Superficial Transitional Cell Carcinoma of Bladder Completed NCT00047216 Phase 2 tipifarnib
43 A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract Completed NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
44 Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Completed NCT01824329 Phase 2
45 An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or Without Investigational Therapy as Second-line Therapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy Completed NCT01282463 Phase 2 Docetaxel
46 Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin Completed NCT00003129 Phase 2 valrubicin
47 PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION Completed NCT00002919 Phase 2 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine sulfate
48 Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Transitional Cell Carcinoma of the Bladder Completed NCT00136175 Phase 2 Paclitaxel;Carboplatin;Gemcitabine
49 Phase II Study of Intravesical Gemcitabine in Patients With Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG Completed NCT00234039 Phase 2 gemcitabine hydrochloride
50 A Phase II, Multicenter Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma Completed NCT00461851 Phase 2 Gemcitabine;Carboplatin;Sorafenib

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Doxorubicin
Thiotepa

Genetic Tests for Bladder Urothelial Carcinoma

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29

Anatomical Context for Bladder Urothelial Carcinoma

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

41
Prostate, Lymph Node, Testes, Lung, Kidney, Brain, Bone

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

19
Lining Of The Bladder

Publications for Bladder Urothelial Carcinoma

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 2652)
# Title Authors PMID Year
1
Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. 9 38
17311305 2007
2
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. 9 38
17293658 2007
3
Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. 9 38
15733109 2005
4
[Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67]. 9 38
12731328 2003
5
Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. 9 38
11696726 2001
6
Expression of pS2 protein and its relation with the Ki-67 proliferative indices and tumor recurrence in superficial bladder carcinomas. 9 38
11528193 2001
7
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. 9 38
11342899 2001
8
The role of bcl-2, p53, and ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. 9 38
10687971 2000
9
Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. 9 38
10699635 2000
10
p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. 9 38
9187909 1997
11
[Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. 9 38
9275651 1996
12
Expression of p53 product in Chinese human bladder carcinoma. 9 38
7688167 1993
13
Re: Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. 38
31184534 2019
14
Bilateral Diffuse Uveal Melanocytic Proliferation Associated With Bladder Cancer: A Novel Imaging Finding. 38
31415702 2019
15
A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma. 38
31396730 2019
16
Identification of five long noncoding RNAs signature and risk score for prognosis of bladder urothelial carcinoma. 38
31373406 2019
17
Prognostic value and reproducibility of different microscopic characteristics in the WHO grading systems for pTa and pT1 urinary bladder urothelial carcinomas. 38
31412916 2019
18
Down-regulated RBM5 inhibits bladder cancer cell apoptosis by initiating an miR-432-5p/β-catenin feedback loop. 38
31318608 2019
19
The Occurrence of Metronidazole-Induced Encephalopathy in Cancer Patients: A Hospital-Based Retrospective Study. 38
31359955 2019
20
Lynch syndrome and urologic malignancies: a contemporary review. 38
31045926 2019
21
Development of a novel six-long noncoding RNA signature predicting survival of patients with bladder urothelial carcinoma. 38
31338862 2019
22
Prognostic impact of tumor infiltrating lymphocytes in bladder urothelial carcinoma. 38
31392149 2019
23
MRS1754 inhibits proliferation and migration of bladder urothelial carcinoma by regulating mitogen-activated protein kinase pathway. 38
30565699 2019
24
Surgical approach as a determinant factor of clinical outcome following radical cystectomy: Does Enhanced Recovery After Surgery (ERAS) level the playing field? 38
31285114 2019
25
Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer. 38
31253481 2019
26
Integrative Analysis of Genomic and Clinical Data Reveals Intrinsic Characteristics of Bladder Urothelial Carcinoma Progression. 38
31212967 2019
27
The Impact of Narrow Band Imaging in the Detection and Resection of Bladder Tumor in Transitional Cell Carcinoma of the Bladder: A Prospective, Blinded, Sequential Intervention Randomized Controlled Trial. 38
30822478 2019
28
Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. 38
30548659 2019
29
Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening. 38
31303453 2019
30
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism. 38
31221981 2019
31
Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study. 38
31262032 2019
32
A Simple Immunohistochemical Panel Could Predict and Correlate to Clinicopathologic and Molecular Subgroups of Urinary Bladder Urothelial Carcinoma. 38
31085058 2019
33
Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. 38
31216997 2019
34
Overexpression of CEP72 Promotes Bladder Urothelial Carcinoma Cell Aggressiveness via Epigenetic CREB-Mediated Induction of SERPINE1. 38
30953603 2019
35
Corrigendum to "The landscape of chimeric RNAs in bladder urothelial carcinoma" [Int. J. Biochem. Cell Biol. 110 (February) (2019) 50-58, Epub ahead of print]. 38
30965217 2019
36
The landscape of chimeric RNAs in bladder urothelial carcinoma. 38
30818082 2019
37
lncRNA CCAT1 promotes bladder cancer cell proliferation, migration and invasion. 38
31038865 2019
38
Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. 38
31239241 2019
39
High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder. 38
30660494 2019
40
Diagnostic accuracy of urine cytokeratin 20 for bladder cancer: A meta-analysis. 38
29931834 2019
41
The clinicopathological characteristics and prognostic value of squamous differentiation in patients with bladder urothelial carcinoma: a meta-analysis. 38
31011874 2019
42
Identifying Potential Prognostic Markers for Muscle-Invasive Bladder Urothelial Carcinoma by Weighted Gene Co-Expression Network Analysis. 38
31011911 2019
43
The long non-coding RNA LINC00460 predicts the prognosis and promotes the proliferation and migration of cells in bladder urothelial carcinoma. 38
30881506 2019
44
Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. 38
31028363 2019
45
Patterns of Urachal Remnant Involvement by Urothelial Carcinoma: Intraluminal Noninvasive Spread Can Mimic a Deep-seated Bladder Invasion. 38
30475253 2019
46
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 38
30279015 2019
47
Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: implications for cell cycle regulation and cell adhesion maintenance. 38
31036064 2019
48
Diagnosis of urinary bladder urothelial carcinoma by immunocytology with p53, MCM5, MCM2 and Ki-67 antibodies using cell blocks derived from urine. 38
30943322 2019
49
Downregulation of the cytochrome P450 4B1 protein confers a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. 38
30803053 2019
50
The ERH gene regulates migration and invasion in 5637 and T24 bladder cancer cells. 38
30866868 2019

Variations for Bladder Urothelial Carcinoma

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 276)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 MAP2K1 NM_002755.3(MAP2K1): c.370C> T (p.Pro124Ser) single nucleotide variant Pathogenic rs1057519732 15:66729162-66729162 15:66436824-66436824
2 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
3 PIK3CA NM_006218.4(PIK3CA): c.2176G> A (p.Glu726Lys) single nucleotide variant Pathogenic rs867262025 3:178938934-178938934 3:179221146-179221146
4 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
5 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
6 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
8 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
9 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
10 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
11 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 17:7577556-7577556 17:7674238-7674238
12 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
13 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
14 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
15 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
16 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
17 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
18 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
19 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
20 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
21 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
22 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
23 NRAS NM_002524.5(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs121434596 1:115258744-115258744 1:114716123-114716123
24 BRAF NM_004333.6(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic rs121913357 7:140481403-140481403 7:140781603-140781603
25 BRAF NM_004333.6(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
26 BRAF NM_004333.6(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic rs121913338 7:140453154-140453154 7:140753354-140753354
27 BRAF NM_004333.6(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
28 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic rs121913482 4:1803564-1803564 4:1801837-1801837
29 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 4:1803568-1803568 4:1801841-1801841
30 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
31 BRAF NM_004333.6(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic rs397507483 7:140453148-140453148 7:140753348-140753348
32 BRAF NM_004333.6(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic rs121913355 7:140481402-140481402 7:140781602-140781602
33 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
34 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
35 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
36 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
37 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
38 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic rs786201059 17:7577082-7577082 17:7673764-7673764
39 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
40 HRAS NM_005343.4(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 11:534285-534285 11:534285-534285
41 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
42 PIK3CA NM_006218.4(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 3:178952074-178952074 3:179234286-179234286
43 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 17:7577580-7577580 17:7674262-7674262
44 IDH1 NM_005896.3(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 2:209113112-209113112 2:208248388-208248388
45 TP53 NM_000546.5(TP53): c.527G> A (p.Cys176Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs786202962 17:7578403-7578403 17:7675085-7675085
46 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 17:7577114-7577114 17:7673796-7673796
47 PIK3CA NM_006218.4(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 3:178936093-178936093 3:179218305-179218305
48 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 8:38272308-38272308 8:38414790-38414790
49 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
50 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893

Expression for Bladder Urothelial Carcinoma

Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.

Pathways for Bladder Urothelial Carcinoma

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.18 TP53 PIK3CA NRAS MAP2K1 KRAS IDH1
2
Show member pathways
13.98 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
3
Show member pathways
13.87 PIK3CA NRAS MAP2K1 KRAS IDH1 HRAS
4
Show member pathways
13.84 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
5
Show member pathways
13.81 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
6
Show member pathways
13.71 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
7
Show member pathways
13.7 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
8
Show member pathways
13.66 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
9
Show member pathways
13.59 TP53 PIK3CA NRAS KRAS HRAS FGFR3
10
Show member pathways
13.52 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
11
Show member pathways
13.44 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
12
Show member pathways
13.44 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
13
Show member pathways
13.42 NRAS KRAS HRAS FGFR3 FGFR1 ERBB2
14
Show member pathways
13.34 TP53 NRAS MAP2K1 KRAS HRAS ERBB2
15
Show member pathways
13.23 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
16
Show member pathways
13.18 TP53 NRAS MAP2K1 KRAS HRAS CTNNB1
17
Show member pathways
13.17 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
18
Show member pathways
13.16 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
19
Show member pathways
13.15 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
20
Show member pathways
13.12 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
21
Show member pathways
13.12 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
22
Show member pathways
13.09 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
23
Show member pathways
13.08 PIK3CA NRAS MAP2K1 KRAS HRAS ERBB2
24
Show member pathways
13.07 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
25
Show member pathways
13.07 PIK3CA NRAS MAP2K1 KRAS HRAS ERBB2
26
Show member pathways
13.04 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
27
Show member pathways
13.04 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
28
Show member pathways
13.03 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
29
Show member pathways
13.01 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
30
Show member pathways
12.98 PIK3CA NRAS MAP2K1 KRAS HRAS BRAF
31
Show member pathways
12.97 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
32
Show member pathways
12.97 NRAS MAP2K1 KRAS HRAS CTNNB1 BRAF
33 12.94 TP53 NRAS MAP2K1 KRAS HRAS FGFR3
34
Show member pathways
12.91 TP53 PIK3CA NRAS KRAS HRAS FGFR3
35
Show member pathways
12.9 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
36
Show member pathways
12.89 PIK3CA MAP2K1 KRAS HRAS BRAF
37
Show member pathways
12.88 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
38
Show member pathways
12.86 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
39
Show member pathways
12.85 TP53 NRAS MAP2K1 KRAS HRAS BRAF
40
Show member pathways
12.84 PIK3CA NRAS MAP2K1 KRAS HRAS CTNNB1
41 12.82 PIK3CA NRAS MAP2K1 KRAS HRAS FGFR3
42
Show member pathways
12.82 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
43
Show member pathways
12.8 NRAS MAP2K1 KRAS HRAS BRAF
44
Show member pathways
12.78 TP53 PIK3CA NRAS KRAS HRAS ERBB2
45
Show member pathways
12.77 PIK3CA NRAS KRAS HRAS FGFR3 FGFR1
46
Show member pathways
12.76 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
47 12.76 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
48
Show member pathways
12.73 PIK3CA NRAS MAP2K1 KRAS HRAS
49
Show member pathways
12.73 PIK3CA NRAS MAP2K1 KRAS HRAS
50 12.73 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS

GO Terms for Bladder Urothelial Carcinoma

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.99 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
2 negative regulation of gene expression GO:0010629 9.92 MAP2K1 HRAS FGFR1 CTNNB1
3 positive regulation of protein kinase B signaling GO:0051897 9.83 PIK3CA FGFR3 FGFR1 ERBB2
4 cellular response to drug GO:0035690 9.78 TP53 NFE2L2 BRAF
5 negative regulation of neuron apoptotic process GO:0043524 9.78 PIK3CA KRAS HRAS BRAF
6 peptidyl-tyrosine phosphorylation GO:0018108 9.77 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
7 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.76 NRAS KRAS HRAS
8 Ras protein signal transduction GO:0007265 9.71 TP53 NRAS KRAS HRAS
9 thymus development GO:0048538 9.67 MAP2K1 CTNNB1 BRAF
10 positive regulation of MAPK cascade GO:0043410 9.65 HRAS FGFR3 FGFR1 ERBB2 CTNNB1
11 negative regulation of apoptotic process GO:0043066 9.63 TP53 CTNNB1 BRAF
12 positive regulation of phospholipase C activity GO:0010863 9.62 HRAS FGFR1
13 positive regulation of MAP kinase activity GO:0043406 9.62 KRAS HRAS FGFR1 ERBB2
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 TP53 MAP2K1
15 positive regulation of phospholipase activity GO:0010518 9.6 FGFR3 FGFR1
16 lung-associated mesenchyme development GO:0060484 9.59 FGFR1 CTNNB1
17 response to isolation stress GO:0035900 9.58 KRAS HRAS
18 regulation of axon regeneration GO:0048679 9.57 MAP2K1 BRAF
19 positive regulation of gene expression GO:0010628 9.56 TP53 NFE2L2 MAP2K1 KRAS HRAS ERBB2
20 trachea formation GO:0060440 9.55 MAP2K1 CTNNB1
21 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.46 MAP2K1 HRAS FGFR3 BRAF
22 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.24 PIK3CA
23 MAPK cascade GO:0000165 9.23 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
24 phosphatidylinositol phosphorylation GO:0046854 9.13 PIK3CA
25 phosphorylation GO:0016310 10.03 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.88 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
2 kinase activity GO:0016301 9.85 PIK3CA MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
3 protein C-terminus binding GO:0008022 9.73 MAP2K1 HRAS ERBB2 CTNNB1
4 protein phosphatase binding GO:0019903 9.63 TP53 ERBB2 CTNNB1
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.58 FGFR3 FGFR1 ERBB2
6 protein tyrosine kinase activity GO:0004713 9.35 MAP2K1 FGFR3 FGFR1 ERBB2 BRAF
7 fibroblast growth factor-activated receptor activity GO:0005007 9.32 FGFR3 FGFR1
8 nucleotide binding GO:0000166 9.23 NRAS MAP2K1 KRAS HRAS FGFR3 FGFR1
9 1-phosphatidylinositol-3-kinase activity GO:0016303 8.96 PIK3CA
10 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 8.85 PIK3CA

Sources for Bladder Urothelial Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....